WO2012103810A1 - Certain chemical entities, compositions, and methods - Google Patents

Certain chemical entities, compositions, and methods Download PDF

Info

Publication number
WO2012103810A1
WO2012103810A1 PCT/CN2012/070817 CN2012070817W WO2012103810A1 WO 2012103810 A1 WO2012103810 A1 WO 2012103810A1 CN 2012070817 W CN2012070817 W CN 2012070817W WO 2012103810 A1 WO2012103810 A1 WO 2012103810A1
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
chemical entities
certain chemical
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2012/070817
Other languages
French (fr)
Inventor
Xiangping Qian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Neupharma Co Ltd
Original Assignee
Suzhou Neupharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Neupharma Co Ltd filed Critical Suzhou Neupharma Co Ltd
Priority to EP12741863.0A priority Critical patent/EP2670763B1/en
Priority to EP18181484.9A priority patent/EP3453714B1/en
Priority to CN201280016457.0A priority patent/CN103619865B/en
Publication of WO2012103810A1 publication Critical patent/WO2012103810A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C07J71/0021—Oxiranes at position 14(15)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J19/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 by a lactone ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Disclosed are the compounds, pharmaceutical compositions thereof, and the uses of the compounds for the treatment of cancer.
PCT/CN2012/070817 2011-02-02 2012-02-01 Certain chemical entities, compositions, and methods Ceased WO2012103810A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP12741863.0A EP2670763B1 (en) 2011-02-02 2012-02-01 Certain chemical entities, compositions, and methods
EP18181484.9A EP3453714B1 (en) 2011-02-02 2012-02-01 Cardenolide and bufadienolide 3-carbonate and 3-carbamate derivatives for the treatment of cancer and compositions thereof
CN201280016457.0A CN103619865B (en) 2011-02-02 2012-02-01 Some chemical individual, compositions and method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161438945P 2011-02-02 2011-02-02
US61/438,945 2011-02-02

Publications (1)

Publication Number Publication Date
WO2012103810A1 true WO2012103810A1 (en) 2012-08-09

Family

ID=46577833

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2012/070817 Ceased WO2012103810A1 (en) 2011-02-02 2012-02-01 Certain chemical entities, compositions, and methods

Country Status (4)

Country Link
US (4) US9493503B2 (en)
EP (2) EP2670763B1 (en)
CN (1) CN103619865B (en)
WO (1) WO2012103810A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014075077A1 (en) * 2012-11-12 2014-05-15 Neupharma, Inc. Certain chemical entities, compositions, and methods
US9249111B2 (en) 2011-09-30 2016-02-02 Neupharma, Inc. Substituted quinoxalines as B-RAF kinase inhibitors
US9249110B2 (en) 2011-09-21 2016-02-02 Neupharma, Inc. Substituted quinoxalines as B-raf kinase inhibitors
US9295671B2 (en) 2011-08-26 2016-03-29 Neupharma, Inc. Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer
US9518029B2 (en) 2011-09-14 2016-12-13 Neupharma, Inc. Certain chemical entities, compositions, and methods
US9670180B2 (en) 2012-01-25 2017-06-06 Neupharma, Inc. Certain chemical entities, compositions, and methods
US9688635B2 (en) 2012-09-24 2017-06-27 Neupharma, Inc. Certain chemical entities, compositions, and methods
US10179141B2 (en) 2010-01-15 2019-01-15 Suzhou Neupharma Co., Ltd. Certain chemical entities, compositions, and methods
US10344048B2 (en) 2011-02-02 2019-07-09 Neupharma, Inc. Certain chemical entities, compositions, and methods
US10487108B2 (en) 2012-04-29 2019-11-26 Neupharma, Inc. Certain steroids and methods for using the same in the treatment of cancer

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102656179B (en) 2010-08-28 2015-07-29 苏州润新生物科技有限公司 Bufafalin derivatives, their pharmaceutical compositions and uses
US20240207256A1 (en) * 2021-05-12 2024-06-27 Neupharma, Inc Certain chemical entities, compositions, and methods

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3981982A (en) * 1974-09-11 1976-09-21 Abbott Laboratories Radioimmunoassay for determining the digoxin content of a sample
US4064227A (en) * 1975-03-17 1977-12-20 Mallinckrodt, Inc. Radioimmunoassay method for the determination of cardiotonic glycosides
US4082747A (en) * 1975-10-01 1978-04-04 Mallinckrodt, Inc. Chemical process
US4115539A (en) * 1976-05-17 1978-09-19 Union Carbide Corporation Analytical or clinical derivatives, tagged derivatives and methods of analysis using such derivatives
US4273866A (en) * 1979-02-05 1981-06-16 Abbott Laboratories Ligand analog-irreversible enzyme inhibitor conjugates and methods for use
EP0270937A2 (en) * 1986-12-09 1988-06-15 Miles Inc. Stable immobilized hapten reagent for use in heterogeneous immunometric assays
EP0297290A2 (en) * 1987-06-10 1989-01-04 Miles Inc. Method for magnetically separating labeled reagent in an immunometric binding assay
EP0297292A2 (en) * 1987-06-10 1989-01-04 Miles Inc. Method and test device for separating labeled reagent in an immunometric binding assay
US5045480A (en) * 1989-02-09 1991-09-03 Miles Inc. Gel particles having hapten moieties bound thereto as immunoassay reagent
US5604091A (en) * 1984-03-01 1997-02-18 Microgenics Corporation Methods for protein binding enzyme complementation
US5846514A (en) 1994-03-25 1998-12-08 Isotechnika, Inc. Enhancement of the efficacy of nifedipine by deuteration
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US20080050731A1 (en) * 2006-02-10 2008-02-28 Invitrogen Corporation Labeling and detection of nucleic acids
CN101400690A (en) * 2006-01-09 2009-04-01 英国技术集团国际有限公司 Hypoxia inducible factor-1 modulators and related uses
CN102203112A (en) * 2010-01-15 2011-09-28 苏州润新生物科技有限公司 Certain chemical entities, compositions, and methods

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1034404A (en) 1910-07-12 1912-07-30 Oliver Chilled Plow Works Engine gang-plow.
US1017914A (en) 1910-10-15 1912-02-20 Harold Ashton Richardson Cement steel plate.
US1006598A (en) 1911-04-15 1911-10-24 Emerson Electric Mfg Co Post-bracket.
DE2013032C3 (en) 1970-03-19 1978-12-07 Hoechst Ag, 6000 Frankfurt 3-Amino-cardenolide, process for their preparation and their use in combating cardiovascular diseases
US3901882A (en) 1970-07-24 1975-08-26 Hoffmann La Roche 3-amino cardenolides and bufadienolides, derivatives and salts thereof
CH559219A5 (en) 1970-07-24 1975-02-28 Hoffmann La Roche Cardenolides and bufadienolides from oxime mixtures and 3-substitution - reaction - having inotropic activity with short latent time and short
DE2526689C2 (en) 1975-06-14 1983-08-11 Hoechst Ag, 6230 Frankfurt Process for the preparation of 2,5-dioxo-1,2-oxa-phospholanes
CA1131241A (en) * 1976-05-17 1982-09-07 William A. Eisenhardt, Jr. Siloxy blocked isocyanate compounds
DE3587549T2 (en) * 1984-10-29 1994-02-17 Microgenics Corp SUPPLEMENTARY TEST PROCEDURE OF PROTEIN BINDING ENZYMES.
DD256134A1 (en) * 1985-06-06 1988-04-27 Akad Wissenschaften Ddr METHOD FOR THE PREPARATION OF DERIVATIVES OF CARDENOLIDES AND CARDENOLIDE ANALOGIC COMPOUNDS
EP0218010A3 (en) 1985-07-10 1988-01-07 Abbott Laboratories Ligand detection method and substituted carboxyfluorescein tracers therefor
US6060598A (en) 1990-05-15 2000-05-09 Hyperion, Inc. Fluorescence immunoassays using fluorescent dyes free of aggregation and serum binding
WO1993025197A1 (en) * 1992-06-12 1993-12-23 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
US5922703A (en) * 1993-09-24 1999-07-13 The Procter & Gamble Company Urethane-containing aminosteroid compounds
US5503982A (en) 1993-09-30 1996-04-02 Research Corporation Technologies, Inc. Detection of an acute myocardial infarction in a patient
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
US5891855A (en) 1996-02-12 1999-04-06 The Scripps Research Institute Inhibitors of leaderless protein export
BR9707495A (en) 1996-02-13 1999-07-27 Zeneca Ltd Quinazoline derivative process for the preparation of the same pharmaceutical composition and process for the production of an antiangiogenic effect and / or reduction of vascular permeability in a warm-blooded animal
US6291455B1 (en) 1996-03-05 2001-09-18 Zeneca Limited 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
SK288365B6 (en) 1999-02-10 2016-07-01 Astrazeneca Ab Intermediates for preparation of angiogenesis inhibitory quinazoline derivatives
US6579857B1 (en) 1999-06-11 2003-06-17 Evanston Northwestern Healthcare Research Institute Combination cancer therapy comprising adenosine and deaminase enzyme inhibitors
EP1278763B1 (en) 2000-04-28 2007-02-14 Inflazyme Pharmaceuticals, Ltd. 3-nitrogen-6,7-dioxygen steroids and uses related thereto
NZ522074A (en) 2000-05-31 2004-06-25 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (en) 2000-06-06 2005-10-17 Астразенека Аб Quinazoline derivatives for the treatment of tumours and a pharmaceutical composition
CN1255392C (en) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 Colceicol derivatives as angiogenesis inhibitors
IL153484A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
WO2002014343A1 (en) 2000-08-17 2002-02-21 Terness, Peter Bufadienolide derivatives and use as immunosuppressive, antiinflammatory and analgesic agents
AU2002217841A1 (en) * 2000-11-06 2002-05-15 Trustees Of Boston University Neuroactive steroid derivatives and methods of use
US20040082521A1 (en) 2002-03-29 2004-04-29 Azaya Therapeutics Inc. Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases
CA2418458A1 (en) 2003-02-06 2004-08-06 Neokimia Inc. Total synthesis of 14 beta-fluorosteroids via the transannular diels-alder reaction
WO2006002381A1 (en) 2004-06-24 2006-01-05 Wisconsin Alumni Research Foundation Neoglycorandomization and digitoxin analogs
US8507411B2 (en) 2004-06-24 2013-08-13 Wisconsin Alumni Research Foundation Neoglycorandomization and digitoxin analogs
US20060009506A1 (en) * 2004-07-09 2006-01-12 Odyssey Thera, Inc. Drugs for the treatment of neoplastic disorders
US20080027010A1 (en) * 2004-09-02 2008-01-31 Bionaut Pharmaceuticals, Inc. Treatment of refractory cancers using Na+/K+-ATPase inhibitors
EP1928470A4 (en) 2005-08-02 2010-09-15 Bionaut Pharmaceuticals Inc Modulators of hypoxia inducible factor-1 and related uses for the treatment of ocular disorders
CN100569793C (en) 2006-02-08 2009-12-16 赵军 A class of bufasterene compounds and their application in drug preparation
WO2007090385A2 (en) * 2006-02-09 2007-08-16 B.Braun Melsungen Ag Coating method for a folded balloon
CN101177445B (en) 2006-11-08 2012-07-04 山东绿叶制药有限公司 Novel bufadienolide compound as well as preparation method and uses thereof
WO2010017480A1 (en) 2008-08-07 2010-02-11 Centrose, Llc Glycoside compounds and pharmaceutical compositions thereof
CZ303037B6 (en) * 2009-05-28 2012-03-07 Ústav organické chemie a biochemie, Akademie ved CR, v. v. i. Pregnanolone derivatives substituted in position 3 alpha, process for their preparation and use
CA2809819A1 (en) 2009-09-09 2011-03-17 Centrose, Llc Extracellular targeted drug conjugates
CN102656179B (en) 2010-08-28 2015-07-29 苏州润新生物科技有限公司 Bufafalin derivatives, their pharmaceutical compositions and uses
US9493503B2 (en) 2011-02-02 2016-11-15 Neupharma, Inc. Certain chemical entities, compositions, and methods
US20130005696A1 (en) 2011-06-30 2013-01-03 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Bufadienolide derivatives, preparing process thereof, composition comprising the same and the use thereof
CN102532235B (en) 2011-06-30 2014-06-04 中国科学院上海药物研究所 Bufogenin derivative and preparation method thereof, composition containing bufogenin derivative and applications thereof
WO2013165924A1 (en) 2012-04-29 2013-11-07 Neupharma, Inc. Certain chemical entities, compositions, and methods

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3981982A (en) * 1974-09-11 1976-09-21 Abbott Laboratories Radioimmunoassay for determining the digoxin content of a sample
US4064227A (en) * 1975-03-17 1977-12-20 Mallinckrodt, Inc. Radioimmunoassay method for the determination of cardiotonic glycosides
US4082747A (en) * 1975-10-01 1978-04-04 Mallinckrodt, Inc. Chemical process
US4115539A (en) * 1976-05-17 1978-09-19 Union Carbide Corporation Analytical or clinical derivatives, tagged derivatives and methods of analysis using such derivatives
US4273866A (en) * 1979-02-05 1981-06-16 Abbott Laboratories Ligand analog-irreversible enzyme inhibitor conjugates and methods for use
US5604091A (en) * 1984-03-01 1997-02-18 Microgenics Corporation Methods for protein binding enzyme complementation
EP0270937A2 (en) * 1986-12-09 1988-06-15 Miles Inc. Stable immobilized hapten reagent for use in heterogeneous immunometric assays
EP0297290A2 (en) * 1987-06-10 1989-01-04 Miles Inc. Method for magnetically separating labeled reagent in an immunometric binding assay
EP0297292A2 (en) * 1987-06-10 1989-01-04 Miles Inc. Method and test device for separating labeled reagent in an immunometric binding assay
US5045480A (en) * 1989-02-09 1991-09-03 Miles Inc. Gel particles having hapten moieties bound thereto as immunoassay reagent
US5846514A (en) 1994-03-25 1998-12-08 Isotechnika, Inc. Enhancement of the efficacy of nifedipine by deuteration
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
CN101400690A (en) * 2006-01-09 2009-04-01 英国技术集团国际有限公司 Hypoxia inducible factor-1 modulators and related uses
US20080050731A1 (en) * 2006-02-10 2008-02-28 Invitrogen Corporation Labeling and detection of nucleic acids
CN102203112A (en) * 2010-01-15 2011-09-28 苏州润新生物科技有限公司 Certain chemical entities, compositions, and methods

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
"Handbook of Pharmaceutical Excipients", 2000, AMERICAN PHARMACEUTICAL ASSOCIATION, AND PHARMACEUTICAL PRESS
"Recent Advances in the Synthesis and Applications of Radiolabeled Compounds for Drug Discovery and Development", IN: CURR., PHARM. DES., 2000, vol. 6, no. 10, 2000, pages 110
"Remington: The Science and Practice of Pharmacy", 2005, LIPPINCOTT WILLIAMS & WILKINS
"Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING COMPANY
ANNUNZIATO M.E. ET AL.: "p-Maleimidophenyl isocyanate: a novel heterobifunctional linker for hydroxyl to thiol coupling", BIOCONJUGATE CHEMISTRY, vol. 4, no. 3, 1993, pages 212 - 218, XP002074803 *
CHEN, SHAOPING ET AL.: "Advances in research on anticancer effects of cardiac glycosides", PHARM CARE & RES, vol. 9, no. 6, December 2009 (2009-12-01), pages 401 - 404, XP008170420 *
EVANS, E.: "Anthony. Synthesis of radiolabeled compounds", J. RADIOANAL. CHEM., vol. 64, no. 1-2, 1981, pages 9 - 32
GAO, MOJIE ET AL.: "Apoptosis of HepG2 cell induced by ouabain and cinobufogenin through ERK signaling pathway", CHINA PHARMACY, vol. 21, no. 27, 2010, pages 2500 - 2503, XP008170270 *
GEORGE W.; VARMA; RAJENDER S.: "The Synthesis of Radiolabeled Compounds via Organometallic Intermediates", TETRAHEDRON, vol. 45, no. 21, 1989, pages 6601 - 21
GRIFFIN, JANE F. ET AL.: "The effect of 16 beta -substitution on the structure and activity of digitoxigenin: Is there an additional binding interaction with sodium-potassium ATPase?", MOLECULAR PHARMACOLOGY, vol. 29, no. 3, 1986, pages 270 - 274, XP008170229 *
HASHIMOTO T. ET AL.: "Cardiac glycosides. 6. Gitoxigenin C16 acetates, formates, methoxycarbonates, and digitoxosides. Synthesis and Na+,K+-ATPase inhibitory activities", JOURNAL OF MEDICINAL CHEMISTRY, vol. 29, no. 6, 1986, pages 997 - 1003, XP055091856 *
MICHAEL; IRENE ASH; GOWER: "Handbook of Pharmaceutical Additives", 1995
OCHI T. ET AL.: "Synthetic study of a cardiac steroid, marinoic acid", J. SCHOOL SCI. ENG., vol. 41, 2005, pages 17 - 22, XP055091858 *
See also references of EP2670763A4 *
TEMPLETON J.F. ET AL.: "Synthesis of 3 beta,14-dihydroxy-5 beta,14 beta-pregnan-20-one C-3 derivatives: ozonolysis of digitoxin and digitoxigenin and their derivatives followed by zinc-acetic acid reduction to the C-21 methyl ketone", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1, vol. 1, no. 4, 1991, pages 823 - 829, XP055091950 *
V. EUW J. ET AL.: "Glycosides and aglucones. C. Sargenoside ("sarmentoside B") and some derivatives of sarmentogenin", HELVETICA CHIMICA ACTA, vol. 35, 1952, pages 1560 - 1577, XP055091866 *

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10912784B2 (en) 2010-01-15 2021-02-09 Suzhou Neupharma Co., Ltd. Certain chemical entities, compositions, and methods
US10179141B2 (en) 2010-01-15 2019-01-15 Suzhou Neupharma Co., Ltd. Certain chemical entities, compositions, and methods
US10471078B2 (en) 2010-01-15 2019-11-12 Suzhou Neupharma Co., Ltd. Certain chemical entities, compositions, and methods
US10344048B2 (en) 2011-02-02 2019-07-09 Neupharma, Inc. Certain chemical entities, compositions, and methods
US10766920B2 (en) 2011-02-02 2020-09-08 Neupharma, Inc. Certain chemical entities, compositions, and methods
US9295671B2 (en) 2011-08-26 2016-03-29 Neupharma, Inc. Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer
US9572808B2 (en) 2011-08-26 2017-02-21 Neupharma, Inc. Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer
US10561652B2 (en) 2011-08-26 2020-02-18 Neupharma, Inc. Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer
US10137125B2 (en) 2011-08-26 2018-11-27 Neupharma, Inc. Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer
US9518029B2 (en) 2011-09-14 2016-12-13 Neupharma, Inc. Certain chemical entities, compositions, and methods
US10759766B2 (en) 2011-09-14 2020-09-01 Neupharma, Inc. Certain chemical entities, compositions, and methods
US9822081B2 (en) 2011-09-14 2017-11-21 Neupharma, Inc. Certain chemical entities, compositions, and methods
US10065932B2 (en) 2011-09-14 2018-09-04 Neupharma, Inc. Certain chemical entities, compositions, and methods
US9249110B2 (en) 2011-09-21 2016-02-02 Neupharma, Inc. Substituted quinoxalines as B-raf kinase inhibitors
US9249111B2 (en) 2011-09-30 2016-02-02 Neupharma, Inc. Substituted quinoxalines as B-RAF kinase inhibitors
US9670180B2 (en) 2012-01-25 2017-06-06 Neupharma, Inc. Certain chemical entities, compositions, and methods
US9908866B2 (en) 2012-01-25 2018-03-06 Neupharma, Inc. Certain chemical entities, compositions, and methods
US10590106B2 (en) 2012-01-25 2020-03-17 Neupharma, Inc. Certain chemical entities, compositions, and methods
US10487108B2 (en) 2012-04-29 2019-11-26 Neupharma, Inc. Certain steroids and methods for using the same in the treatment of cancer
US11325940B2 (en) 2012-04-29 2022-05-10 Neupharma, Inc. Certain chemical entities, compositions, and methods
US10457641B2 (en) 2012-09-24 2019-10-29 Neupharma, Inc. Certain chemical entities, compositions, and methods
US9688635B2 (en) 2012-09-24 2017-06-27 Neupharma, Inc. Certain chemical entities, compositions, and methods
US10047059B2 (en) 2012-11-12 2018-08-14 Neupharma, Inc. Substituted quinoxalines for inhibiting kinase activity
US9725421B2 (en) 2012-11-12 2017-08-08 Neupharma, Inc. Substituted quinoxalines as B-raf kinase inhibitors
WO2014075077A1 (en) * 2012-11-12 2014-05-15 Neupharma, Inc. Certain chemical entities, compositions, and methods

Also Published As

Publication number Publication date
EP2670763B1 (en) 2018-08-01
CN103619865B (en) 2016-10-12
US20200354398A1 (en) 2020-11-12
EP3453714A2 (en) 2019-03-13
EP3453714A3 (en) 2019-03-27
EP3453714B1 (en) 2020-11-04
EP2670763A4 (en) 2014-11-12
US20120196842A1 (en) 2012-08-02
US9493503B2 (en) 2016-11-15
US20200024303A1 (en) 2020-01-23
EP2670763A1 (en) 2013-12-11
US10344048B2 (en) 2019-07-09
US20170088580A1 (en) 2017-03-30
CN103619865A (en) 2014-03-05
US10766920B2 (en) 2020-09-08

Similar Documents

Publication Publication Date Title
WO2012103810A1 (en) Certain chemical entities, compositions, and methods
EP2747767B8 (en) Certain chemical entities, compositions, and methods
AU2013216320A8 (en) C10RF32 Antibodies, And Uses Thereof For Treatment Of Cancer
AU2016204248A1 (en) Boron-Containing Molecules
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
HK1199100A1 (en) Methods and compositions for the treatment and diagnosis of colorectal cancer
WO2013120022A3 (en) Treatment of hypoglycemia
WO2014113089A3 (en) Signal-sensor polynucleotides for the alteration of cellular phenotypes
WO2012100224A3 (en) Preparation of metal-triazolate frameworks
WO2012065022A3 (en) Spiro-oxindole mdm2 antagonists
EP2967049A4 (en) Methods, compounds, and compositions for the treatment of angiotensin-related diseases
WO2012118812A3 (en) Substituted 6,5-fused bicyclic heteroaryl compounds
WO2012177844A3 (en) Substituted imidazopyridinyl-aminopyridine compounds
WO2012116237A3 (en) Heterocyclic compounds and uses thereof
HK1206028A1 (en) Phenicol antibacterials
PH12014502032A1 (en) Treatment of brain cancer
EP2665706A1 (en) Novel 4-amino-n-hydroxy-benzamides as hdac inhibitors for the treatment of cancer
WO2014097318A3 (en) Agents for eliminating tumour-initiating cells
WO2012017321A3 (en) Treatment for dyslipidemia
HK1254231A1 (en) Mito-honokiol compounds and methods of synthesis and use thereof
WO2013052108A3 (en) Methods and compositions for the treatment and diagnosis of ovarian cancer
WO2012170720A3 (en) Methods and compositions for treating brain cancer
WO2012061012A3 (en) 4-amino-2h-pyran-2-one analogs as anticancer agents
EP3089745A4 (en) Compounds, compositions, and methods for the treatment of cancers
WO2012106702A3 (en) Treatment of leukemia

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12741863

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012741863

Country of ref document: EP